ABT - Company ID 0000001800
The table below shows ABBOTT LABORATORIES's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $13.01B | $12.59B | $11.16B | $11.37B | $11.14B | $10.36B |
| Cost of revenue | $5.63B | $5.33B | $4.89B | $5.08B | $4.85B | $4.47B |
| Gross profit | - | - | - | - | - | - |
| R&D | $920.00M | $892.00M | $767.00M | $766.00M | $725.00M | $716.00M |
ABBOTT LABORATORIES reported annual revenue of $44.33B for fiscal year 2025. That is up 5.7% from $41.95B in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $20.85B (FY 2016) to $44.33B. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $4.27B |
| $4.03B |
| $3.74B |
| $3.05B |
| $3.09B |
| $3.06B |
| Operating income | $1.36B | $1.69B | $1.34B | $2.06B | $2.05B | $1.69B |
| Income tax | $311.00M | $596.00M | $372.00M | $536.00M | $371.00M | $453.00M |
| Net income | $920.00M | $928.00M | $1.08B | $1.64B | $1.78B | $1.32B |
| EPS (diluted) | $0.53 | $0.53 | $0.61 | $0.94 | $1.01 | $0.76 |